Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Diabetes Mellitus among Patients Diagnosed with Giant Cell Arteritis or Granulomatosis with Polyangiitis: Comparison with the General Population

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lymphopenia and neutropenia are associated with subsequent incident proteinuria in Danish patients with systemic lupus erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Algorithmic prediction of HIV status using nation-wide electronic registry data

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Patients with organ- or life-threatening vasculitis receive high cumulative glucocorticoid (GC) doses during their disease course. GC have diabetogenic effects, but the risk of diabetes mellitus (DM) related to vasculitis therapy is not well characterized. We assessed the DM risk among patients diagnosed with giant cell arteritis (GCA) or granulomatosis with polyangiitis (GPA), i.e., patients with relatively common forms of systemic vasculitis.

METHODS: We used Danish healthcare registries to identify 1682 patients diagnosed with GCA and 342 patients diagnosed with GPA from 1997 to 2015 and to obtain information regarding medication exposures. Each patient with vasculitis was matched with 9 population controls. Date of new-onset DM was defined as date of first claimed prescription for an antidiabetic drug. We used Cox regression analyses to calculate incidence rate ratios (IRR) for DM as a measure of the DM risk among patients relative to population controls. Logistic regression was used to study the association between prednisolone/prednisone (PRED) dose and DM.

RESULTS: Median duration of followup was 6.5 years [interquartile range (IQR) 2.6-10.4] in the GCA cohort and 5.8 years (IQR 1.7-10.6) in the GPA cohort. During the first year after diagnosis of vasculitis, the IRR for DM was 7.0 (95% CI 5.2-9.3) among patients with GCA and 10.4 (95% CI 4.4-24) among patients with GPA. IRR for DM were not significantly increased in either cohort during later followup periods. Within the first year, treatment with high cumulative prednisolone/PRED doses was associated with new-onset DM among the patients with vasculitis.

CONCLUSION: Patients diagnosed with GCA or GPA have a markedly increased risk of new-onset DM during early treatment phases.

Original languageEnglish
JournalJournal of Rheumatology
Volume44
Issue number1
Pages (from-to)78-83
ISSN0315-162X
DOIs
Publication statusPublished - 2017

ID: 49201530